What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Chemotherapy
His primary scientific interests are in Internal medicine, Surgery, Oncology, Chemotherapy and Melanoma.
As part of his studies on Internal medicine, he often connects relevant subjects like Gastroenterology.
His Surgery research includes elements of Interferon and Subgroup analysis.
His Oncology research is multidisciplinary, relying on both Meta-analysis, Clinical trial, Proportional hazards model and Immunology.
His biological study spans a wide range of topics, including Prospective cohort study and Pharmacology.
His research investigates the connection with Melanoma and areas like Cancer which intersect with concerns in Cutaneous melanoma and Antigen.
His most cited work include:
- Autologous or Allogeneic Bone Marrow Transplantation Compared with Intensive Chemotherapy in Acute Myelogenous Leukemia (781 citations)
- Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy (721 citations)
- Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial (717 citations)
What are the main themes of his work throughout his whole career to date?
His scientific interests lie mostly in Internal medicine, Oncology, Surgery, Gastroenterology and Melanoma.
His work in Hazard ratio, Leukemia, Chemotherapy, Randomized controlled trial and Cancer are all subfields of Internal medicine research.
His research in Hazard ratio tackles topics such as Decitabine which are related to areas like Azacitidine.
The study incorporates disciplines such as Myeloid leukemia and Immunology in addition to Oncology.
He interconnects Survival rate, Vincristine, Acute lymphocytic leukemia and Asparaginase in the investigation of issues within Gastroenterology.
His Melanoma course of study focuses on Adjuvant therapy and Meta-analysis.
He most often published in these fields:
- Internal medicine (81.88%)
- Oncology (47.32%)
- Surgery (39.60%)
What were the highlights of his more recent work (between 2013-2021)?
- Internal medicine (81.88%)
- Oncology (47.32%)
- Hazard ratio (20.47%)
In recent papers he was focusing on the following fields of study:
Stefan Suciu mainly investigates Internal medicine, Oncology, Hazard ratio, Surgery and Placebo.
His Internal medicine study combines topics from a wide range of disciplines, such as Gastroenterology and Melanoma.
Stefan Suciu combines subjects such as Survival rate, Idarubicin, Chemotherapy and Asparaginase with his study of Gastroenterology.
His Oncology research incorporates elements of Azacitidine and Myeloid leukemia, Immunology.
His research integrates issues of Survival analysis, Randomized controlled trial, Proportional hazards model and Decitabine in his study of Hazard ratio.
His work carried out in the field of Surgery brings together such families of science as Toxicity and Surrogate endpoint.
Between 2013 and 2021, his most popular works were:
- Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy (721 citations)
- Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial (717 citations)
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma (659 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
Internal medicine, Hazard ratio, Oncology, Surgery and Melanoma are his primary areas of study.
His Placebo research extends to the thematically linked field of Internal medicine.
His Hazard ratio research integrates issues from Decitabine, Proportional hazards model, Myelodysplastic syndromes, Randomization and Survival analysis.
In his research, Maintenance therapy and Vincristine is intimately related to Confidence interval, which falls under the overarching field of Oncology.
His Surgery research includes themes of Gastroenterology and Toxicity.
His work deals with themes such as Adjuvant and Alpha interferon, which intersect with Melanoma.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
